Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Dabur India Q3 Revenue Surges 34.5% To Rs 1452.68 Crore - The Pharma Times | Pharma & Health Care News Portal
Categories: National

Dabur India Q3 Revenue Surges 34.5% To Rs 1452.68 Crore

Consolidated Net Profit for the quarter rises 12% To Rs 172.82 Crore

New Delhi, January 31st, 2012: The Board of Directors of Dabur India Ltd (DIL) met here today to consider the unaudited financial results of the company for the quarter and Nine-month period ended December 31, 2011.

Riding on strong volume-driven growth across its key categories like Hair Oils, Health Supplements, Foods, Toothpaste & Home Care, Dabur India Ltd ended the third quarter of 2011-12 financial year with a 34.5% surge in consolidated Net Sales to Rs 1,452.68 Crore. Consolidated Net sales stood at Rs 1,079.97 Crore in the same quarter last year. While the macro-economic environment continues to be challenging, a host of consumer connect initiatives and higher investment behind our brands helped Dabur drive demand for its products in both urban and rural markets. The Company ended the third quarter of the current fiscal with a near 12% rise in consolidated Net Profit to Rs 172.82 Crore, up from Rs 154.44 Crore a year earlier.

Net Profit for the nine-month period ending December 31, 2011 marked a 12.52% growth to Rs 474.38 Crore, while Net Sales for the same period was up 32.01% at Rs 3,919.59 Crore.

“Despite the Inflationary pressures and macro-economic challenges, we have managed our business dynamically through a combination of judicious price increases and greater focus on cost efficiencies. We have also enhanced investment behind our brands, which will yield dividend in months to come. As a result, our EBITDA marked a 12% growth during the quarter. Going forward too, we will continue to pursue an aggressive and profitable growth strategy,” Dabur India Ltd Chief Executive Officer Mr. Sunil Duggal said.

Category Growths

The Hair Oils business for Dabur – led by strong growth in both Amla & Vatika brands – ended the third quarter with a 22% growth, while the Digestives business reported a 19.3% growth. Dabur’s Home Care category – riding on sustained demand for Odonil air fresheners – ended the period with an 18% gain. The Foods business reported a 17.4% growth during the quarter. Dabur continued to be among the fastest growing toothpaste companies in India with the category reporting a robust 14.4% growth. The Health Supplements category ended the quarter with a 13.5% growth.The quarter marked Dabur’s foray into the professional grooming space with the launch of professional facial kits under the brand Fem. The company has launched Fem Gold & Fem Queen’s Pearl professional facial kits, both of which have been very well received by the market. The Company is now adding to this portfolio with the launch of India’s first body bleach, also under the Fem brand. Dabur also entered the Almond hair oil market during this period.

Dabur’s International Business continues to be a key growth driver, recording a robust 37.8% growth (excluding acquisitions) during the third quarter of the current fiscal, led by strong performance in GCC, Egypt and Nigeria. “The Nigeria business reported a 33% growth, while sales in GCC markets grew by 27% during the quarter. Egypt too reported a 25% growth. Shampoos, Hair Creams and Toothpastes were the key growth drivers in the international markets. We will continue to pursue an aggressive growth strategy,” Dabur India Ltd Group Director Mr. P D Narang said.

http://www.dabur.com/en/home/home.asp

The Pharma Times News Bureau

Recent Posts

Ramaiah Memorial Hospital Launches Novel Intra-Operative Radiation Therapy (IORT);

Achieves significant advancement in Cancer Treatment to Enhance Quality of Life  As per the National…

20 hours ago

Two Complex Robotic Kidney Transplant Surgeries Successfully Performed at Fortis Hospital Bannerghatta Road

-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…

2 days ago

On International Nurses Day, American Oncology Institute (AOI) launches #TheExtraordinaryCareGiver Campaign as Tribute to Oncology Nurses

Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…

3 days ago

SOCC Unveils A New Era In Paediatric Care: Second Opinion Online Consultations For Children

Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…

6 days ago

India’s First Lady Surgeon Trained in Robotic Breast Surgery Performs Karnataka’s 1st Robotic Nipple Sparing Mastectomy

Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…

1 week ago

Fortis Hospital, Bannerghatta Road Launches dedicated Parkinson’s Disease and Deep Brain Stimulation Clinic

-  This specialized division empowers patients with neurological disorders to reclaim their mobility through a…

2 weeks ago

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home2/theprkho/public_html/thepharmatimes.in/wp-includes/functions.php on line 5420